Introduction
The diverse functions of the neurohypophysial peptide hormones [argininex] vasopressin (AVP) and oxytocin (OT) are mediated by a family of receptor proteins expressed in both the central nervous system and peripheral tissues [1, 2] . cDNA clones encoding five vasopressin receptors (VPRs) and two oxytocin receptors (OTRs) have now been isolated from rodent, porcine and human sources [3-91. These proteins are members of the larger family of G-protein-coupled receptors (GPCRs), which have seven putative transmembrane domains. Sequence comparison of the neurohypophysial peptide hormone receptors reveals two highly conserved domains in the putative first (ECII) and second (ECIII) extracellular (EC) loops which we [9] and others [lo-121 have hypothesized to play a role in ligand binding. To test this hypothesis, we synthesized peptide mimics of the extracellular domains of neurohypophysial peptide hormone receptors. The rationale employed in this investigation was to determine whether molecular recognition occurs between isolated receptor domains and peptidelnon-peptide ligands. Using this approach, we have identified binding-site determinants in the extracellular domains of the rat V,, VPR (rV ,,R) which selectively 'recognize' neurohypophysial hormones. We propose that these domains are closely associated in the native receptor protein to form an extracellular ligandbinding site.
Experimental
Peptide mimics of extracellular receptor domains (Table 1) OTR, oxytocin receptor; pKi, -log[K,(M)]; rV,,R, rat V,, VPR; rV,R, rat V, VPR SR49059, (2S)-1-[(2R,3S)-(5-chloro-3-(2-chlorophenyl)-1 -( 3,4-dimethoxybenzene--sulphonyl)-3-hydroxy2,3-dihydro-1 H-indole-2-carbony-11 -pyrrolidine -2 -carboxamide; VPR, vasopressin receptor. *To whom correspondence should be addressed. phase methodology. Carboxy-amidated peptides were purified by semi-preparative-scale h.p.1.c. and lyophilized [13] . The purity and identity of each peptide was confirmed by a combination of analytical h.p.l.c., amino acid analysis and m.s. [13] . Peptides were dissolved at a concentration of 0.5-5 mM and stored at -20°C.
Effect of receptor mimics on ligand binding
As a strategy to study molecular recognition, we employed a ligand-binding protocol in which the interaction of a radiolabelled ligand with a receptor mimic would reduce radioligand occupancy of the rV,,R. T o aid comparison of binding data, all assays were performed as previously described [ 13-1.51 using a single preparation of rat liver membranes with a V,, capacity of 600fmol/mg of membrane protein. We chose to use the V,,R preparation as both peptide and non-peptide high-affinity radioligands for this receptor are commercially available. This meant that we could undertake a comprehensive dissection of ligand-recognition determinants. The radioligands used were the natural agonist 
. To evaluate specificity, an identical protocol was used to determine whether synthetic peptide mimics of neurohypophysial peptide receptors would reduce the specific binding of [3H]angiotensin I1 (['HIAngII, 71.5 Ci/ mmol) to the rat liver AT, receptor. Apparent inhibition constants were determined by non-linear regression after the fitting of a simple Langmuir binding isotherm to experimental data using the Effect of receptor mimics on hormone-stimulated glycogen phosphorylase, activity I04 the incorporation of radioactive glucose from [ a-u-[U -''C]glucose 1-phosphate into glycogen [18] . In order to determine whether receptor mimetic peptides could inhibit AVP-and AngIIstimulated GP, activity, we compared two rV,,R ECII mimics. T o allow formation of peptide-ligand complexes, peptides were pre-incubated with 0.5 nM AVP or 10 nM AngII at 37°C in physiological buffer, then stored on ice until required. Rat hepatocytes (4.5 x lo6 cells/ml) were incubated at 37°C for 20min before the addition of agonists or agonist/peptide mixtures. After a further 2 min, incubations were terminated by rapid freezing in liquid N,. Subsequently, GP, activity was assayed in homogenized cells as previously described [ 181.
Results
The inherent solubility of the majority of peptides synthesized in this study allowed us to routinely use concentrations of 50.1 mM in binding assays. Using this methodology, we were able to accurately determine the apparent K, for most of the peptides used. As shown in Figure 1 , receptor mimetic peptides inhibited radioligand binding in a dosedependent manner. Comparative data (Table 1) indicate that peptide mimics of the ECII domain of the rV,,R and human OTR (hOTR) were the most effective inhibitors of the binding of all three radioligands. Thus, the 12-mers DITYRFRGPDWL (rV,,R) and DITFRFYGPDLL (hOTR) displayed apparent pK, values in the range 6.25-6.75. Comparison of the two rV,,R ECII mimics clearly demonstrated that a reduction in size from the 12-mer (DITYRFRGPDWL) to the 8-mer (TYRFRGPD) reduced apparent affinity by two orders of magnitude. In contrast, the peptide mimic of the rat V, VPR (rV,R) ECII domain (DATDRF-HGPDAL) interacted weakly with only AVP and did not inhibit the binding of either ['HI-[d(CH&Tyr(Me) ']AVP or ['HISR 49059 (Table 1 and Figure 1) .
Using a series of overlapping peptides to mimic the complete extracellular surface of the rV,,R, we were able to identify two further sites within the ECI and ECIII domains which also inhibited radioligand binding ( Figure 1 and Table 1 ). The peptide DENFIWTDSEN, which corresponds to the relatively short ECIV domain of the rV,,R, was without effect (Table 1) . As a control, we tested all peptide mimics for their ability to reduce ['HI AngII binding. At concentrations of 10-100pM none of the peptides used in this study reduced ligand occupancy of the rat liver AT, receptor.
As indicated in Figure l(d) , the ECII mimics DITYRFRGPDWL and TYRFRGPD both inhibited AVP-stimulated GP, activity with IC,, values of 7.9 and 400,uM respectively. Neither of these peptides inhibited AngII-stimulated GP, activity.
Discussion
Our data demonstrate that the use of peptide mimetics is a successful method for determining the functional domains of GPCRs. The specificity of this approach is confirmed by our findings that not all of the peptides used in this study inhibited the binding of V,, VPR ligands and that none of them inhibited ['HIAngII binding to the rat AT, receptor. A synthetic peptide approach has previously been used to investigate the extracellular ligand-binding domain of GPCRs which bind relatively large glycoprotein hormones [ 19-2 11. Our findings indicate that such an approach is also valid for the investigation of the ligand-binding domain of GPCRs which interact with smaller peptide hormones.
Our data reveal that conserved amino acids within the first extracellular loop and a section of the second loop (ECII and ECIII domains, Figure  2 ) comprise a major determinant of the extracellular ligand-binding site of the rV,,R. As similar domains are a feature of GPCRs of lower vertebrates which bind the hormone vasotocin [ l l ] , it is tempting to speculate that these domains have an ancient evolutionary origin as vasotocin is believed to be the ancestral precursor of the mammalian hormone AVP [22] . In order for the ECII and ECIII domains of the native V,, VPR to participate in ligand binding we propose that these extracellular loops are linked by a disulphide bridge between Cys-124 and Cys-20.5 (Figure 2) [17, 18] . Thus, the properties of the ECII mimics appear to parallel some features of the pharmacology of native VPRs but do not exclusively determine ligand selectivity.
As indicated in Figure 2 , the amino acid sequence of the N-terminal ECI domain of the neurohypophysial peptide hormone receptors is not highly conserved in this family of receptor proteins. However, as revealed by the properties of the mimetic peptide DRSVGNSSPWWPLTTE, this domain does contribute to the ligand-binding site of the V,, VPR. Part of this amino acid sequence, GNSSPWWPL, is preserved in the human V,,
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I995 Table I Comparative inhibition constants for receptor mimetic peptides One other important conclusion to be drawn from this study on the rV,,R derives from our observation that the binding-site mimics inhibit, with similar potency, the binding of all three classes of radioligand. These results strongly imply that some of the binding-site determinants for vasopressin agonists and antagonists (peptide and nonpeptide) are identical or that they overlap to a significant degree. This finding contrasts with studies on other GPCRs [28-311 which have inferred that the binding-site determinants for peptides and non-peptide ligands are different.
As predicted from our observation that soluble receptor binding-site mimics inhibit ligand binding to the rV,,R, our data indicate that the formation of a specific ligand-peptide complex selectively reduces agonist activity. These findings substantiate the hypothesis [ 321 that the soluble ligand-binding domains of receptors have therapeutic potential as a new class of drug.
There is now substantial evidence to support the contention that molecular recognition of the extracellular domains of GPCRs is a widespread mechanism by which peptide ligands selectively bind to GPCRs. Indeed, such a mechanism appears to mediate the binding of a variety of different agonists and antagonists which range in size from the relatively small tripeptide formyl peptides to glycoproteins with molecular masses of > 30 000 [19] [20] [21] 24, [26] [27] [28] [29] [30] [31] [33] [34] [35] [36] [37] [38] . W e conclude that GPCRs which selectively bind the neurohypophysial peptide hormones can be added to the growing list of cloned GPCRs for which extracellular domains contribute part of the ligand-binding site.
Volume 23 Figure 2 Model of the rat V,, VPR
The predicted domain structure of the extracellular surface is illustrated. ECI-ECIV represent extracellular domains 1-4. Residues which are conserved in all mammalian VPRs [3, 5] are shown with solid circles. Superimposed upon this structure (asterisks) are the span of peptides which contain binding-site determinants for VPR ligands. 
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